General Instructions
Word Count: All abstract categories (with the exception of Encore submissions) have a 300-count word limit.
Original Research: Early Decision Abstract Deadline: February 15, 2022, 11:59 p.m. (PST); Regular Decision Abstract Deadline: June 15, 2022, 11:59 p.m. (PST)
Word Count: All abstract categories (with the exception of Encore submissions) have a 300 count word limit.
Abstracts must summarize quantitative or qualitative findings from completed research. Basic, clinical, translational, dissemination/implementation, or educational research are examples of acceptable research. Topics should appeal to a clinical pharmacy audience and may include research in drug metabolism, education/pedagogy, health services, medication safety, patient/population outcomes, pharmacokinetics, pharmacodynamics, pharmacoeconomics, pharmacoepidemiology, pharmacogenomics, pharmacology, or pharmacotherapy. Abstracts reporting in vitro or animal research are welcome.
- Abstracts must be structured with the section headers of: Introduction, research question or hypothesis, study design, methods, results, and conclusions.
- Abstracts will be evaluated based on merits of the research question/hypothesis, study design, originality, methods, data analysis, results, and conclusions. For ACCP's specific evaluation criteria, click here.
- Descriptions of planned research efforts or preliminary data will not be accepted.
- To be eligible for Best Poster, Student Best Poster, or Resident/Fellow Best Poster the abstract must fit and be submitted in this category. For specific eligibility criteria, click here.
- Original research findings presented (in abstract form) elsewhere, but important to clinical pharmacy, are encouraged as “Encore” submissions (see Encore Presentation details below).
- A previously presented abstract may form the basis for a new abstract to be submitted for consideration in the Original Research category if the previous abstract:
- was a descriptive report of planned research only,
- described preliminary results only and complete results are now available,
- was presented at a student, resident, or fellow conference focused on gaining presentation experience and/or formative feedback,
- was presented at an ACCP Chapter or PRN event, or
- conclusions have been added/modified based on a new hypothesis and data analysis of the original results database.
Systematic Reviews/Meta-Analyses:Early Decision Abstract Deadline: February 15, 2022, 11:59 p.m. (PST); Regular Decision Abstract Deadline: June 15, 2022, 11:59 p.m. (PST)
Word Count: All abstract categories (with the exception of Encore submissions) have a 300-count word limit.
Abstracts must describe a systematic review adhering to the guidelines and definitions established by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA, http://www.prisma-statement.org/) and include the 12-items published in the PRISMA for Abstracts checklist (http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001419).
- Abstracts must be structured with the PRISMA for Abstracts format: Background, methods, results, discussion, and other.
- Abstracts will be evaluated based on merits of the 12 PRISMA for Abstracts checklist items: Title, objectives, eligibility criteria, information sources, risk of bias, included studies, synthesis of results, description of the effect, strengths and limitations of evidence, interpretation, funding, and registration. For ACCP’s specific evaluation criteria, click here.
- Abstracts presented elsewhere, but important to clinical pharmacy, are encouraged as “Encore” submissions (see Encore Presentation details below).
Case Reports: Early Decision Abstract Deadline: February 15, 2022, 11:59 p.m. (PST); Regular Decision Abstract Deadline: June 15, 2022, 11:59 p.m. (PST)
Word Count: All abstract categories (with the exception of Encore submissions) have a 300-count word limit.
Abstracts of case reports must update and expand therapeutic insights and possibilities or generate research hypotheses. While narrative in nature, these abstracts must stress the "evidence" for the authors' conclusions by describing the process followed to understand the findings and possible mechanisms involved in the patient's case, how the patient was evaluated and treated, and a specific description of the outcome.
- Abstracts must be structured with the section headers: Introduction, case, discussion, and conclusion.
- Case report abstracts will be evaluated based on the abstract criteria recommended by the CARE Guidelines (CAse REport Group, http://www.care-statement.org/resources/checklist): uniqueness of report, clinical findings presented, outcomes documented, and “take-away” lessons. For ACCP’s specific evaluation criteria, click here.
- Abstracts of case reports presented elsewhere, but important to clinical pharmacy, are encouraged as “Encore” submissions (see Encore Presentation details below).
Clinical Pharmacy Forum: Early Decision Abstract Deadline: February 15, 2022, 11:59 p.m. (PST); Regular Decision Abstract Deadline: June 15, 2022, 11:59 p.m. (PST)
Word Count: All abstract categories (with the exception of Encore submissions) have a 300-count word limit.
Abstracts must describe the delivery of, justification or documentation for, and impact/significance of innovative clinical pharmacy services previously implemented. Abstracts that address components of the ACCP Standards of Practice for Clinical Pharmacists (see www.accp.com/standards) and/or describe efforts to develop, advance, or position clinical pharmacists to optimize patient care are encouraged. Abstracts may be descriptive and need not contain an evaluative component.
- Abstracts must be structured with the section headers of: Service or program, justification/documentation, adaptability, and significance.
- Descriptions of planned services or programs will not be accepted.
- Abstracts will be evaluated based on originality of the service or program, adequacy of justification/documentation, adaptability to other settings, and significance to clinical pharmacy. For ACCP’s specific evaluation criteria, click here.
- Abstracts presented elsewhere, but important to clinical pharmacy, are encouraged as “Encore” submissions (see Encore Presentation details below).
Advances in International Clinical Pharmacy Practice, Education, or Training: Early Decision Abstract Deadline: February 15, 2022, 11:59 p.m. (PST); Regular Decision Abstract Deadline: June 15, 2022, 11:59 p.m. (PST)
Word Count: All abstract categories (with the exception of Encore submissions) have a 300-count word limit.
Abstracts must describe the delivery of, justification or documentation for, and significance of clinical pharmacy practice, education, or training outside of the United States. Abstracts may be descriptive and need not contain an evaluative component.
- Abstracts must be structured with the section headers of: Service or program, justification/documentation, adaptability, and significance.
- Abstracts will be evaluated based on the originality of the service or program to the specific setting, adequacy of justification/documentation, adaptability to other settings, and significance to international clinical pharmacy advancement. For ACCP’s specific criteria, click here.
Residents and Fellows Research-in-Progress: Early Decision Abstract Deadline: February 15, 2022, 11:59 p.m. (PST); Regular Decision Abstract Deadline: July15, 2022, 11:59 p.m. (PST)
Word Count: All abstract categories (with the exception of Encore submissions) have a 300-count word limit.
Submission guidelines are those of an Original Research abstract except that the research effort is ongoing at the time of abstract submission.
- The presenting author must be in a post-graduate training program (PGY-1 or PGY-2 residency, Ph.D./Masters graduate degree program, or fellowship training program).
- Abstracts submitted in the Research-in-Progress category are not eligible for the Resident and Fellow Best Poster competition. *Note: to be eligible for the Best Poster competition, the research must meet the criteria for and be submitted under the Original Research category, indicating that it was conducted by a resident or fellow.
- All papers will be assigned to poster format.
- In-Progress abstracts will be published in the Meeting App, only.
Student Research-in-Progress: Early Decision Abstract Deadline: February 15, 2022, 11:59 p.m. (PST); Regular Decision Abstract Deadline: June 15, 2022, 11:59 p.m. (PST)
Word Count: All abstract categories (with the exception of Encore submissions) have a 300-count word limit.
Submission guidelines are those of an Original Research abstract except that the research effort is ongoing at the time of abstract submission.
- The presenting author must be a first professional degree (Pharm.D. or B.S. Pharm.) student. Note: students in Ph.D./Master's degree programs are welcome in the Resident and Fellow Research-in-Progress category.
- Abstracts submitted in the Research-in-Progress category are not eligible for the Student Best Poster competition. *Note: to be eligible for the Best Poster competitions, the research must meet the criteria for and be submitted under the Original Research category, indicating that it was conducted by a student.
- All papers will be assigned to poster format.
- In-Progress abstracts will be published in the Meeting App, only.
Encore Presentation: Early Decision Abstract Deadline: February 15, 2022, 11:59 p.m. (PST); Regular Decision Abstract Deadline: June 15, 2022, 11:59 p.m. (PST)
Word Count: All abstract categories (with the exception of Encore submissions) have a 300-count word limit. Submission and evaluation criteria are those of the Original Research, Systematic Review/Meta-Analysis, or Case Reports, categories, except that the same abstract was presented elsewhere or published
in abstract form only prior to this meeting.
- Abstracts submitted for Encore Presentations must not be modified from the previously presented/published version. This includes the title, authors, and abstract body. The presenting author may change, but they must be an author on the original abstract.
- The same abstract may not be presented at more than one national ACCP event.
- The full abstract will be published in the Meeting App, only.
- Only the abstract title, authors, and original citation will be published in JACCP.
- Encore Presentations will not be eligible for the Best Poster Awards.
- Submit Encore Presentation abstracts as under the Encore Abstracts section. Select Original Research, Systematic Review/Meta-Analysis, or Case Reports when prompted. Provide the original citation when prompted and include a copy of the original abstract in the Abstract Text section of the submission database.
Selection Notification:
- Early submission abstract authors will be notified by e-mail of acceptance or declination of their abstracts by April15, 2022.
- Regular submission abstract authors will be notified by email of acceptance or declination of their abstracts by August 15, 2022.
ACCP Best Poster Competitions
Student Best Poster Competition:
To be considered for this award:
- Research must have been conducted by the primary author while a first professional degree student (B.S. Pharm or Pharm.D.).
- The primary author must be the presenter of the poster.
- Abstract submission must occur within one year of the primary author’s completion of first professional degree.
- Papers must represent completed research and be submitted under the Original Research category. Papers submitted in the Student Research in Progress category are not eligible for this competition.
Resident/Fellow Best Poster Competition:
To be considered for this award:
- Research must have been conducted by the primary author while a post-Pharm.D. resident or fellow trainee.
- The primary author must be the presenter of the poster.
- Abstract submission must occur within one year of the primary author’s completion of training program.
- Papers must represent completed research and be submitted under the Original Research category. Papers submitted in the Resident and Fellow Research in Progress category are not eligible for this competition.
Best Poster Competition:
To be considered for this award:
- Research must have been conducted by the primary author.
- The primary author must be the presenter of the poster.
- Students, residents and fellows are not eligible for this award.
- Papers must represent completed research and be submitted under the Original Research category.